Nouhad Husseini
Director/Board Member bei DECIBEL THERAPEUTICS, INC.
Profil
Nouhad Husseini is currently the Director & Managing Director at Checkmate Pharmaceuticals, Inc. and Decibel Therapeutics, Inc. He also holds the position of Senior VP-Business Development at Regeneron Pharmaceuticals, Inc. Husseini completed his undergraduate degree at Princeton University and obtained an MBA from The Wharton School of the University of Pennsylvania.
Aktive Positionen von Nouhad Husseini
| Unternehmen | Position | Beginn |
|---|---|---|
| REGENERON PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.01.2011 |
| CHECKMATE PHARMACEUTICALS, INC. | Director/Board Member | 31.05.2022 |
| DECIBEL THERAPEUTICS, INC. | Director/Board Member | 22.09.2023 |
Ausbildung von Nouhad Husseini
| Princeton University | Undergraduate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| REGENERON PHARMACEUTICALS, INC. | Health Technology |
| DECIBEL THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Checkmate Pharmaceuticals, Inc.
 Checkmate Pharmaceuticals, Inc. BiotechnologyHealth Technology Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing proprietary technology to harness the power of the immune system to combat cancer. The firm's product candidate, vidutolimod is a differentiated TLR9 agonist delivered as a biologic virus-like particle designed to trigger the body's innate immune system to attack tumors in combination with other therapies. The company was founded by Arthur M. Krieg and Chuck Yo in July 2015 and is headquartered in Cambridge, MA. | Health Technology |
